Don’t need to I did further research into these types of peptides in this class. All showed safety, pre clinical success but could never show not 1 percent improvement in humans. It’s why the CEO in every interview states that any percentage of success is important even if it’s 1 percent. Even though preclinical success was strong, she knows every peptide in this drug class has failed before and it’s not a reflection of the outcome.
If AGN was a new drug class first of its kind having this safety and pre clinical success I would be more optimistic and certain it would most likely work to hold beyond safety and pre clinical studies coming up because it means that it’s the first of its kind. But also it’s a peptide and this type of drugs has many flaws and it’s why only around 100 peptides have been approved by the FDA since 1921. In it for the period ahead
AGN Media thread, page-187
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 78.0¢ | 80.5¢ | 78.0¢ | $71.40K | 90.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 78.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.5¢ | 2444 | 1 |
View Market Depth
| Last trade - 15.55pm 23/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |